PHILADELPHIA, Sept. 17,
2024 /PRNewswire/ -- Verismo Therapeutics, a
clinical-stage CAR T company developing the novel KIR-CAR platform
technology, today announced that it has been awarded a
$150,000 G-Rex Grant by ScaleReady™.
This grant will support Verismo Therapeutics' ongoing efforts to
optimize the development and manufacturing of its KIR-CAR
platform using the G-Rex.
The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell
and Gene Therapy (CGT) development and manufacturing. The G-Rex
Grant Program offers recipients significant support allowing for
expeditious optimization of cell manufacturing processes.
"We are grateful to have been chosen for the G-Rex Grant at
Verismo Therapeutics," stated Raymond
Luke, Director of Manufacturing Science and Technology at
Verismo Therapeutics. "This funding will help us further
optimize our cell therapy manufacturing processes by transitioning
our active and future pipeline to G-Rex®, ensuring we can deliver
life-saving treatments to patients more efficiently and
cost-effectively. We are excited to work with ScaleReady to drive
forward innovative solutions in cell therapy production."
"We are excited to support Verismo Therapeutics through the
G-Rex Grant program. Their commitment to advancing cell and gene
therapy aligns perfectly with our mission to provide hope to cancer
patients one G-Rex at a time. We look forward to seeing the
impactful advancements Verismo Therapeutics will achieve with this
grant." said John Wilson, CEO of
Wilson Wolf Manufacturing and co-inventor of G-Rex.
As part of the G-Rex® Grant, Verismo will complete
optimization of their G-Rex-based KIR-CAR T process and plans to
implement this as a platform manufacturing process. Additionally,
Verismo will evaluate a suite of critical reagents from Bio-Techne
(R&D Systems) including GMP cytokines. Specifically,
Verismo will get early access to a line of new, closed system
reagents from Bio-Techne, called ProPakTM GMP cytokines,
that are tailor-made for use with G-Rex. The ProPakTM
line of GMP reagents are estimated to be commercially available by
the end of 2024.
Verismo Therapeutics is committed to pioneering new therapies
and technologies that improve patient outcomes. The G-Rex Grant
will play a pivotal role in advancing the company's research and
development efforts, ultimately contributing to the broader goal of
making innovative treatments accessible to those in need.
About the KIR-CAR Platform
The KIR-CAR platform is a multi-chain CAR T cell therapy and has
been shown in preclinical animal models to be capable of
maintaining antitumor T cell activity even in challenging tumor
microenvironments. Using NK cell derived KIR and DAP12 split
signaling provides a novel combined activation and co-stimulation
separate from the usual T cell stimulation pathways. It also
enables sustained chimeric receptor expression and improves KIR-CAR
T cell long term function. This results in prolonged T cell
functional persistence and leads to regression of solid tumors in
preclinical models that are resistant to traditional CAR T cell
therapies.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in multi-chain KIR-CAR
technology, with its first assets SynKIR™-110 and SynKIR™-310
currently in Phase 1 clinical trials. Verismo is the only company
developing the KIR-CAR platform, using a modified NK cell derived
receptor and DAP12 pairing, designed to improve persistence and
efficacy against aggressive tumors. The KIR-CAR platform technology
was developed specifically to address areas of high unmet medical
need, including advanced solid tumors and B cell associated
disorders and malignancies. For more information, visit:
www.verismotherapeutics.com
About ScaleReady™
ScaleReady provides the field of
cell and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 4
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Wilson Wolf Manufacturing Corporation
Wilson Wolf (www.wilsonwolf.com)
is dedicated to simplifying cell and gene-modified cell (CGT)
therapy research, process development, and manufacturing.
This is being accomplished through its scalable G-Rex® technology,
which is used throughout the world in CGT applications ranging from
basic research to commercial drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne, in
partnership with Wilson Wolf, is
creating products such as media and cytokines that are specifically
tailored to G-Rex® Bioreactors, including right-sized reagent
quantities in containers that are tailored to high throughput
closed-system manufacturing. For more information on Bio-Techne and
its brands, please visit https://www.bio-techne.com or
follow the Company on social media
at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/verismo-therapeutics-awarded-a-scaleready-g-rex-grant-302249877.html
SOURCE Verismo Therapeutics
